[Laboratory and clinical studies on cefotaxime in obstetrics and gynecology (author's transl)].
We have conducted basic and clinical examination of a new cephalosporin derivative, cefotaxime (CTX). The average level of transfer measured at various locations in uterus tissue and adnexa 15 to 105 minutes (53.4 minutes in average) after intravenous administration of this drug ranged from 1.5 mcg/g (myometrium) to 3.3 mcg/g (portio vaginalis). It was distributed in cervix uteri and portio vaginalis at highest concentration, followed by oviduct, tunica serosa and ovary, and to myometrium at lowest concentration. The same pattern of distribution was observed in transfer ratio of various location in uterus tissue to uterus arterial blood. The drug was transferred at very high level in pelvic cavity fluid after total hysterectomy throughout 3 postoperative hours. Five cases of gynecological infections receiving in total 10 to 42 g of CTX demonstrated 'excellent' results in 2 cases, and 'good' in 3 cases. Out of these, 3 cases did not respond to other antibiotic. Neither side effect nor clinical test abnormality was observed, except for one case, in which mild increase of GOT and GPT occurred. Based on the results of basic and clinical studies as described above, this drug is considered to have excellent efficacy and safety.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy; D002439:Cefotaxime / Q000378:metabolism* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy; D005836:Genitalia, Female / Q000378:metabolism*; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D010388:Pelvis / Q000378:metabolism; D011247:Pregnancy; D014018:Tissue Distribution; D014599:Uterus / Q000378:metabolism
D002439:Cefotaxime